|
CNBC'S MOST SHARED
- A Goldman Trading Scandal?
- Rich People With A Death Wish
- The Threat of Ballooning Pensions
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- SEC May Reinstate Rules for Short-Selling Stocks
- Market's Monday Blues
- Is Andy’s Mojo Back? We Asked Him
- Your First Move For Monday July 6th
- China Launches Major Step to Yuan Internationalization
- Goldman Sees No Harm From Computer Programmer
- Farrell: Don't Head For The Exits Yet
- Justice Dept Said to Be Looking At Telecom Giants
- Lehman CEO: Firm Deserved Bailout or 'Wind Down'
- US Service Sector Has Best Showing In Months
- GM A Step Closer To Exiting Bankruptcy
- Tribune, Cubs Deal Agreed In Principle
- Facebook Director Sees 'Billions' in Revenue in 5 Years
- Judge Gives Control of Jackson Estate to Executors
- Hey, What's Up Doc?
- Busch: Summertime Blues Hits Investors
- Chadwick: Recession and Scandals Pave the Way for Romney 2012
- Art Cashin: The S&P's 'Head and Shoulders' Number
- Michael Jackson: Death And Taxes
- Is Andy’s Mojo Back? We Asked Him
- GM A Step Closer To Exiting Bankruptcy
- Schork Oil Outlook: The Fear Trade
- Market's Monday Blues
Text Size 
Pharmaceutical giant Merck [MRK
Loading...
()
] said quarterly earnings rose as booming sales of newer medicines offset declines in older products, and said it plans to seek U.S. approval in 2009 for a migraine-headache treatment now entering late-stage trials.
Merck, which on April 12 preannounced the quarterly earnings trends, posted first-quarter net earnings of $1.7 billion, or 78 cents a share, compared with $1.52 billion, or 69 cents a share, a year earlier.
Merck earned 84 cents a share excluding restructuring charges, matching its forecast of last week.
Company sales rose 7% to $5.8 billion, fueled by surging revenue from its newer cholesterol fighters Zetia and Vytorin, new vaccines and the new Januvia diabetes treatment, as well as from strong sales growth of asthma drug Singulair and treatments for high blood pressure.
Merck said its migraine drug MK-0974, a so-called calcitonin gene-related peptide (CGRP) antagonist, is now entering Phase III trials. Data from mid-stage trials of the product will be unveiled at a medical meeting in June, the drugmaker said.
Combined sales of Vytorin and Zetia, which are marketed in partnership with Schering-Plough [SGP
Loading...
()
], grew 47% to $1.2 billion. Singulair sales jumped 25 percent to $1 billion, while combined sales of hypertension drugs Cozaar and Hyzaar rose 14 percent to $798 million. Januvia, a pill introduced in October, posted quarterly sales of $87 million.
Total sales of vaccines -- including Gardasil to prevent cervical cancer and Rotateq to protect against rotavirus infections in young children -- more than tripled to $903 million.
Print
Email
Data is a real-time snapshot *Data is delayed at least 15 minutes